Heart Failure Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital Naples, Via Leonardo Bianchi 1, 80100, Naples, Italy.
Department of Cardiology, Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, USA.
Drugs. 2023 Feb;83(3):195-201. doi: 10.1007/s40265-022-01833-w. Epub 2023 Jan 18.
Pulmonary hypertension, defined as an increase in mean arterial pressure > 20 mmHg, is a chronic and progressive condition with high mortality and morbidity. Drug therapy of patients with pulmonary hypertension is based on the distinctive pathophysiologic aspect that characterizes the different groups. However, recently, levosimendan, a calcium-sensitizing agent with inotropic, pulmonary vasodilator, and cardioprotective properties, has been shown to be an effective and safe therapeutic strategy for patients with pulmonary arterial hypertension (in addition to specific drugs) and pulmonary hypertension associated with left heart disease (as possible treatment). This review provides a comprehensive overview of the current evidence on the use of levosimendan in patients with pulmonary hypertension.
肺动脉高压，定义为平均动脉压升高>20mmHg，是一种慢性且进行性的疾病，具有高死亡率和发病率。肺动脉高压患者的药物治疗基于不同组别的特征性病理生理方面。然而，最近，左西孟旦，一种具有正性肌力、肺血管舒张和心脏保护作用的钙离子增敏剂，已被证明是肺动脉高压（除特定药物外）和左心疾病相关肺动脉高压（可能的治疗方法）患者的有效且安全的治疗策略。这篇综述全面概述了左西孟旦在肺动脉高压患者中的应用的现有证据。
